Alembic Pharmaceuticals Ltd has received tentative approval from the US Food and Drug Administration for brexpiprazole tablets in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg strengths, according to an exchange filing.
The drug is a generic version of Otsuka Pharmaceutical Co Ltd's Rexulti tablets.
It is indicated as adjunctive therapy alongside antidepressants for the treatment of major depressive disorders and schizophrenia.
According to information from IQVIA, the drug's sales for the fiscal year that ended in December 2022 totaled about $1.6 billion.
Sheena Bora Murder Case: Friend Testifies Mikhail Sought Help To Rescue Sheena From Rehab Centre On Indrani Mukerjea’s Instructions
'Everyone Is Geared Up For The Game': Team India's Fielding Coach T. Dilip Reflects On Super 4 Clash Against Pakistan At Asia Cup 2025; Video
Rural Maharashtra Sees Spike In 'Crypto-Christianity' Cases; Alleged Conversions Fuel Communal Tensions
Maharashtra Urdu Sahitya Academy Anniversary Row: Govt Allocates ₹1.2 Crore Against Promised ₹50 Crore
The shares of the company traded 0.7% higher at ₹515.75 on NSE, at 09:15 IST.
